Evercore ISI Group Upgrades Enanta Pharmaceuticals to Outperform, Announces $62 Price Target

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.

Total
0
Shares
Related Posts
Read More

European Stocks Are Left In Shambles From Russia-Ukraine War: It May Be Time To Buy These 2 High Yielders

As the SPDR Portfolio Europe ETF (ARCA: SPEU) is down roughly 32% year-to-date, it may be a prime moment to hunt for stocks that have become undervalued in the European stock market. The SPDR Portfolio Europe ETF seeks to track the performance of the STOXX Europe Total Market Index, which is the European equivalent to the S&P 500 Index here in the U.S.

AZN